Pharmacopeia Inc: Premium Company Profile
Scope
Report Highlights
Reasons to Purchase
Table of Contents
- Overview - page 1
- Catalyst - page 1
- Summary - page 1
- Table of Contents - page 2
- Table of figures - page 3
- Table of tables - page 4
- Company Structure - page 5
- Company Overview and Key Facts - page 5
- Business Description - page 6
- Landmark Products and Services - page 7
- ECLiPS - page 7
- Landmark Products and Services - page 7
- History - page 8
- Company Financials - page 10
- Stock Market Performance - page 10
- P&L - page 11
- Balance Sheet - page 14
- Cash Flow - page 14
- Business Segment Performance - page 15
- Products & Services - page 16
- Pipeline Products - page 16
- In-house Pipeline - page 16
- PS178990 - page 17
- JAK3 - page 17
- CCR1 - page 17
- Adenosine A2A - page 17
- In-house Pipeline - page 16
- AC Forecast Product Sales - page 19
- Pipeline Products - page 16
- Competitors and Strategic Business Relationships - page 20
- Key Competitors - page 20
- Key Suppliers - page 21
- Key Clients - page 21
- Shareholding Structure - page 23
- Strategy - page 24
- Company View - page 24
- Corporate Strategy - page 28
- SWOT Analysis - page 29
- Overview - page 29
- Strengths - page 30
- Collaborations with leading pharmaceutical companies - page 30
- Weaknesses - page 31
- Weak late stage pipeline - page 31
- Opportunities - page 32
- Acquisition of SARM program from BMS - page 32
- Positive results from DARA program - page 32
- Identification of two lead compounds - page 32
- Threats - page 34
- Rigorous and lengthy regulatory processes - page 34
- Value Chain Analysis - page 35
- Overview - page 35
- Discovery and Product Development - page 36
- Scorecard - page 37
- Overview - page 37
- Scorecard Analysis - page 38
- Key Employees - page 39
- List of Key Employees - page 39
- Key Employee Biographies - page 40
- Leslie J Browne - page 40
- Joseph A Mollica - page 40
- Carol A Ammon - page 41
- Frank Baldino - page 41
- Paul A Bartlett - page 42
- Steven Burakoff - page 42
- Dennis H Langer - page 43
- Bruce A Peacock - page 43
- Martin H Soeters - page 44
- David M Floyd - page 44
- Brian M Posner - page 45
- Stephen C Costalas - page 45
- Simon M Tomlinson - page 46
- S David Kimball - page 46
- Rene Belder - page 47
- Maria L Webb - page 47
- Financial and Operational Overview - page 48
- Financial and Operational Overview - page 48
- APPENDIX - page 50
- Ask the analyst - page 50
- Datamonitor consulting - page 50
- Disclaimer - page 50
- List of Tables
- Table 1: Pharmacopeia - Key Facts - page 5
- Table 2: Pharmacopeia - Year-End Share Price and Market Capitalization, 2002-2006 ($) - page 10
- Table 3: Pharmacopeia - Key Events Impacting Share Price Performance - page 10
- Table 4: Pharmacopeia - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) - page 11
- Table 5: Pharmacopeia - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) - page 13
- Table 6: Pharmacopeia - Balance Sheet, 2002-2006 ($ Mn) - page 14
- Table 7: Pharmacopeia - Cash Flow, 2002-2006 ($ Mn) - page 14
- Table 8: Pharmacopeia - Revenue Breakdown, 2002-2006 ($ Mn) - page 15
- Table 9: Pharmacopeia - In-house Pipeline Products - page 16
- Table 10: Pharmacopeia- Key Strategic Revenues, 2006-2010 ($ Mn) - page 19
- Table 11: Pharmacopeia - Key Competitors - page 20
- Table 12: Pharmacopeia - Key Suppliers - page 21
- Table 13: Pharmacopeia - Key Clients - page 21
- Table 14: Pharmacopeia - Key Shareholders - page 23
- Table 15: Pharmacopeia - SWOT Analysis Summary - page 29
- Table 16: Pharmacopeia - Value Chain Analysis - page 35
- Table 17: Pharmacopeia - Scorecard - page 37
- Table 18: Pharmacopeia - Key Employees - page 39
- Table 19: Pharmacopeia - Financial and Operational Overview - page 48
- List of Figures
- Figure 1: Pharmacopeia - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) - page 12
Other users found this report page using the following search terms: pharmacopeia inc program dara stephen pharmacopiea paul price compounds inhouse
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.